

# Melbourne International Joint Breast Congress



Australasian Society  
for Breast Disease  
(ASBD)



4th World Congress on  
Controversies in Breast  
Cancer (CoBrCa)



Breast Surgeons of  
Australia & New Zealand  
(BreastSurgANZ)



---

## CONGRESS PROGRAM

---

Melbourne, Australia  
October 11-13, 2018



[www.melbournebreast2018.org](http://www.melbournebreast2018.org)



# TIMETABLE

## Thursday, October 11, 2018

	Hall A	Hall B	Hall C	Hall D
09:00-12:20		<b>Pre-Congress Workshop 1:</b> From concept to publication: Clinical trials in cancer	<b>Pre-Congress Workshop 2:</b> Pathology – shades of grey: When the answer is non-definitive	<b>Pre-Congress Workshop 3:</b> The challenging patient
12:20-13:20	Lunch break			
13:20-16:40		<b>Pre-Congress Workshop 4:</b> Managing breast cancer in resource poor locations	<b>Pre-Congress Workshop 5:</b> Radiation oncology	<b>Pre-Congress Workshop 6:</b> The tortuous road to diagnosis
16:40-17:15	Break			
17:15-17:30	<b>Congress Opening</b>			
17:30-19:00	<b>Plenary Session 1:</b> Neoadjuvant therapy			
19:00	Networking Reception			

## Friday, October 12, 2018

	Hall A	Hall B	Hall C
07:00-08:30	<b>Morning Industry Symposium:</b> Practice changing new perspectives on genomic profiling in the management of ER+, HER2- Early Breast Cancer <i>Supported by Genomic Health</i>	<b>Morning Industry Symposium:</b> CDK4/6 inhibitors in advanced breast cancer: The future is now <i>Supported by Pfizer</i>	
08:30-09:30	<b>Parallel Session 2:</b> Screening	<b>Parallel Session 3:</b> Keeping patients on their endocrine treatments	<b>Parallel Session 4:</b> Free Papers: Medical oncology
09:30-11:00	<b>Plenary Session 5:</b> Genetics		
11:00-11:30	Coffee break and poster viewing		
11:30-12:30	<b>Parallel Session 6:</b> Imaging	<b>Industry Symposium:</b> Clinical controversies in HER2+ early breast cancer <i>Supported by Roche</i>	<b>Parallel Session 7:</b> Free Papers: Surgery/Radiotherapy
12:30-13:30	Lunch break and poster viewing		
13:30-14:30	<b>Parallel Session 8:</b> Controversies in reconstruction	<b>Industry Symposium:</b> New paradigms in the treatment of HR+HER2- mBC: CDK4/6 inhibitors and beyond <i>Supported by Novartis</i>	
14:30-15:50	<b>Plenary Session 9:</b> Adjuvant endocrine therapy		
15:50-16:10	Coffee break and poster viewing		
16:10-17:30	<b>Parallel Session 10:</b> Molecular assays	<b>Parallel Session 11:</b> Life after breast cancer	

## Saturday, October 13, 2018

	Hall A	Hall B	Hall C
07:00-08:30		<b>Morning Industry Symposium:</b> Old favourites, new strategies: Chemotherapy and the treatment of MBC <i>Supported by Eisai</i>	<b>Morning Industry Symposium:</b> Attractive techniques for localisation and staging: Tools for everyone <i>Supported by Magseed</i>
08:30-09:30	<b>Parallel Session 12:</b> DCIS	<b>Parallel Session 13:</b> Topics in chemotherapy	<b>Parallel Session 14:</b> Free Papers: Screening/Treatment effects/Supportive care
09:30-11:00	<b>Plenary Session 15:</b> Loco-Regional therapy		<b>10:30-13:00</b> <b>Breast Cancer Network Australia</b>
11:00-11:30	Coffee break and poster viewing		
11:30-13:00	<b>Parallel Session 16:</b> Local therapy	<b>Industry Symposium:</b> Key issues around bone health <i>Supported by Amgen</i>	
13:00-14:00	Lunch break and poster viewing		
14:00-15:00	<b>Parallel Session 17:</b> Exercise and lymphoedema	<b>Parallel Session 18:</b> CNS metastases	<b>Parallel Session 19:</b> Breast surgery
15:00-16:15	<b>Plenary Session 20:</b> Breast Cancer 2025		
16:15-16:30	Congress closing and Award presentation		

---

## WELCOME LETTER

---

Dear Friends and Colleagues,

We are pleased to welcome you to the Melbourne International Joint Breast Congress (MIBC), held jointly with the Australasian Society for Breast Disease (ASBD), 4th World Congress on Controversies in Breast Cancer (CoBrCa) and Breast Surgeons of Australia and New Zealand (BreastSurgANZ).

The Joint Congress combines the traditional features of the conferences of all three organisations - a wide multidisciplinary program, in depth analysis of various aspects of breast surgical practice, and an approach of directly addressing key issues facing clinicians in their daily practice. We believe that the collaboration has created a multi-faceted congress of interest to all involved in the treatment of breast disease.

We are delighted to have assembled a stellar international and national faculty, and thank all of those who have agreed to participate and those who have submitted abstracts.

We would like to thank the supporters, without whose backing this congress could not take place, as well as all of you who have travelled from across the city or the world to attend the congress.

We look forward to your participation in the sessions and trust that it is an informative and enjoyable experience.

Enjoy your time in the exciting and modern city of Melbourne.

Sincerely,  
Congress Chairpersons

Yvonne Zissiadis, Australia  
**Australasian Society for  
Breast Disease  
(ASBD)**

Bruce Mann, Australia  
**4th World Congress on  
Controversies in Breast Cancer  
(CoBrCa)**

Christobel Saunders, Australia  
**Breast Surgeons of  
Australia and New Zealand  
(BreastSurgANZ)**





## CPD ACCREDITATION

### Royal Australasian College of Physicians (RACP)

Fellows of the Royal Australasian College of Physicians (RACP) should individually claim CPD credits in the online MyCPD program, based on the number of hours they have attended. The MyCPD program is a self-directed and self-reporting tool enabling participants to record and report on CPD activities they judge relevant to the scope of their practice.

Fellows can claim 1 credit per hour of attendance at the MIBC congress in the MyCPD program.

### Royal Australasian College of General Practitioners (RACGP)

Fellows of the Royal Australasian College of General Practitioners (RACGP) may claim QI&CPD points by self-recording online at the RACGP website [www.racgp.org.au](http://www.racgp.org.au) and supplying a certificate of attendance with the program outline.

### The Royal Australian and New Zealand College of Radiologists (RANZCR)

A total of 20.25 RANZCR CPD points can be claimed for attendance at the Melbourne International Joint Breast Congress (MIBC).

4.75 points may be claimed for attendance on 11/10/2018.

8 points may be claimed for attendance on 12/10/2018.

7.5 points may be claimed for attendance on 13/10/2018.

For anyone who attends only part of a session, points may be claimed pro rata at 1 point per hour per lecture.

### Royal Australasian College of Surgeons

This educational activity has been approved in the RACS CPD Program. Fellows who participate can claim one point per hour in Maintenance of Knowledge and Skills.

Participation in this activity will be populated into your RACS CPD Online.

## MIBC at Your Fingertips

Download the app and gain access to everything you need to know to plan a successful event.

MIBC is proud to introduce the Congress APPLICATION – a state-of-the-art educational tool dedicated to implementing innovative and environmentally-friendly technology. The MIBC App is your best tool for planning and organizing your participation and keeping up to date.

The App can be downloaded via your personal device through both Google Play and Apple stores. In order to access the MIBC congress program, abstracts and other information, please scan the relevant QR code or click on the relevant short link below:



### All Devices

(with this you are able to choose between android or ios once you click on the link or scan the QR code)

Short link: <http://bit.ly/2qtzulg>



### iPhone

Short link:

<http://bit.ly/2qttxVb>



### Android

Short link:

<http://bit.ly/2qtyBsS>



# SCIENTIFIC PROGRAM

## Thursday, October 11, 2018

Hall B

**09:00-12:20**    **Pre-Congress Workshop 1:  
From concept to publication: Clinical trials in cancer**

**Chairperson:**    **Arlene Chan, Australia**

**Speakers:**      **Arlene Chan, Australia** - Medical oncology  
                         **Boon Chua, Australia** - Radiation oncology  
                         **Andrew Spillane, Australia** - Breast surgery

**09:00-09:10**    Opening: Goals and benefits of clinical research  
                         **Arlene Chan, Australia**

**09:10-09:40**    Goals of workshop: Spectrum of research, GCP/NHMRC, trial conduct, protocol basics  
                         **Arlene Chan, Australia**

Questions from the audience

**09:45-10:00**    Phases of clinical trials, protocol development  
                         **Arlene Chan, Australia**

Regulatory, ethics and governance  
**Arlene Chan, Australia**

**10:00-10:30**    Group activity

*10:30-10:50*    *Coffee Break*

**10:50-11:20**    Group presentation and discussion

**11:20-11:40**    Scope and pitfalls of surgical research  
                         **Andrew Spillane, Australia**

**11:40-12:00**    Scope and pitfalls of radiation oncology research  
                         **Boon Chua, Australia**

**12:00-12:15**    How to present at a clinical meeting  
                         **Arlene Chan, Australia**

**12:15-12:20**    Roundup



Hall C

**09:00-12:20**    **Pre-Congress Workshop 2:  
Pathology – shades of grey: When the answer is non-definitive**

**Chairperson:**    **Nirmala Pathmanathan, Australia**

**09:00-09:30**    Spindle cell lesions of the breast and their significance  
**Stephen Fox, Australia**

**09:30-10:00**    The spectrum of lesions from atypia to DCIS and lobular neoplasia, significance and management  
**Sunil Lakhani, Australia**

**10:00-10:30**    Radial scars, papillomas and other benign proliferative lesions, significance and management  
**Gelareh Farshid, Australia**

10:30-10:50    *Coffee Break*

**10:50-11:20**    ER, PR and HER2 testing controversies and the classification of breast cancer  
**David Clouston, Australia**

**11:20-12:10**    Breast cancer prognosis: Is grade still relevant?  
**Nirmala Pathmanathan, Australia**

**12:10-12:20**    Panel discussion

Hall D

**09:00-12:20**    **Pre-Congress Workshop 3:  
The challenging patient**

**Chairperson:**    **Norman Swan, Australia**

**09:00-09:15**    Who are the challenging patients and how do they challenge us?  
**Christobel Saunders, Australia**

**09:15-09:35**    Can we understand their challenges?  
**Jane Turner, Australia**

**09:35-09:55**    What are our legal obligations?  
**Ian Freckelton, Australia**

**09:55-10:15**    The US experience  
**Reshma Jagsi, USA**

**10:15-10:30**    Managing challenging patients clinician-patient encounters  
**Lesley Stafford, Australia**

10:30-10:50    *Coffee Break*

**10:50-12:20**    Panel and audience discussion  
**Christobel Saunders, Australia; Ian Freckelton, Australia; Reshma Jagsi, USA; Lesley Stafford, Australia; Fran Boyle, Australia; Jane Turner, Australia; Alexis Butler, Australia; Kerry Shanahan, Australia; Danielle Spence, Australia**

12:20-13:20    *Lunch Break*

**13:20-16:40**    **Pre-Congress Workshop 4:  
Managing breast cancer in resource poor locations**

**Chairperson:**    **Jacinta Elston, Australia**

**13:20-13:30**    Introduction  
**Jacinta Elston, Australia**

**13:30-14:00**    East Timor - setting up a breast service in one of the world's most resource poor nations  
**Alito Soares, Timor Leste**  
**Danielle Spence, Australia**  
**Christobel Saunders, Australia**

**14:00-14:20**    Developing breast cancer services and advocacy in India  
**Raghu Ram, India**

**14:20-14:40**    How to get radiotherapy to resource-poor nations  
**Mei Ling Yap, Australia**

14:40-15:00    *Coffee Break*

**15:00-15:20**    Breast cancer in Maori and Pasifika  
**Ian Campbell, New Zealand**

**15:20-15:50**    Breast cancer in Indigenous Australia  
**Jacinta Elston, Australia**  
**Jennifer Chynoweth, Australia**

**15:50-16:40**    Panel discussion:  
**Jacinta Elston, Australia; Alito Soares, Timor Leste; Danielle Spence, Australia;**  
**Christobel Saunders, Australia; Raghu Ram, India; Mei-Ling Yap, Australia;**  
**Ian Campbell, New Zealand; Jennifer Chynoweth, Australia; Josese Turageva, Fiji**

**13:20-16:40**    **Pre-Congress Workshop 5:  
Radiation oncology**

**Chairpersons:**    **Minjae Lah, Australia**  
**Yvonne Zissiadis, Australia**

**13:20-13:25**    Welcome and introduction of speakers  
**Minjae Lah, Australia**  
**Yvonne Zissiadis, Australia**

**13:25-13:45**    Post-mastectomy RT in node negative and N1 patients  
**Reshma Jagsi, USA**

**13:45-14:05**    Discussion

**14:05-14:25**    Cardiotoxicity: When do we start to worry?  
**Lori Pierce, USA**

**14:25-14:50**    Discussion

14:50-15:10    *Coffee Break*

**15:10-15:30**    Integrating RT and breast reconstruction  
**Reshma Jagsi, USA**

**15:30-15:45**    Discussion

**15:45-16:00**    Cardio-oncology programs: Part of our quality control?  
**Lori Pierce, USA**

**16:00-16:20**    Q & A



Hall D

**13:20-16:40**     **Pre-Congress Workshop 6:  
The tortuous road to diagnosis**

**Chairperson:**     **Jill Evans, Australia**

**13:20-13:40**     When is a lump a lump?  
**Jennifer O'Sullivan, Australia**

**13:40-14:10**     **Radiology:**  
Breastscreen assessment: Not always smooth sailing  
**Nick Repin, Australia**

**14:10-14:40**     Imaging diagnostic conundrums  
**Liz Wylie, Australia**

14:40-15:00     *Coffee Break*

**15:00-16:00**     **Surgery & Pathology:**  
Uncertainties and grey areas in breast pathology: When is surgical intervention needed?  
**Nirmala Pathmanathan, Australia**  
**Elisabeth Elder, Australia**

**16:00-16:40**     Panel and audience discussion

Hall A

**17:15-17:30**     **Congress Opening**

Hall A

**17:30-19:00**     **Plenary Session 1:  
Neoadjuvant therapy**

**Chairpersons:**     **Richard de Boer, Australia**  
**Christobel Saunders, Australia**

<b>17:30-18:00</b>	<b>DEBATE:</b> That decisions regarding NAST should be based on TN stage rather than breast cancer subtype
17:30	<b>TN stage: Bruce Mann, Australia</b>
17:40	<b>Breast cancer subtypes: Stephen Johnston, UK</b>
17:50	Discussion

**18:00-18:30**     The potential of neoadjuvant endocrine therapy  
**Mitch Dowsett, UK**

<b>18:30-19:00</b>	<b>DEBATE:</b> That further chemotherapy should be recommended for patients with ER-ve cancer not achieving pCR
18:30	<b>Yes: Stacy Moulder, USA</b>
18:40	<b>No: Nicholas Wilcken, Australia</b>
18:50	Discussion

**19:00**             **Networking Reception**



## Friday, October 12, 2018

**07:00-08:30** **Morning Industry Symposium:  
Practice-changing new perspectives on genomic profiling in the management of  
HR+, HER2- Early Breast Cancer**  
*Supported by Genomic Health*

Hall A

*Breakfast will be served prior to the session*

**For full details, please refer to page??**

**07:00-08:30** **Morning Industry Symposium:  
CDK4/6 inhibitors in advanced breast cancer: The future is now**  
*Supported by Pfizer*

Hall B

*Breakfast will be served prior to the session*

**For full details, please refer to page??**

**08:30-09:30** **Parallel Session 2:  
Screening**

Hall A

**Chairpersons:** **Gelareh Farshid, Australia**  
**Allison Rose, Australia**

<b>08:30-09:05</b>	<b>DEBATE:</b> That BreastScreen Australia requires urgent and radical reform
08:30	<b>Yes: Alexandra Barratt, Australia</b>
08:40	<b>No: Bruce Mann, Australia</b>
08:50	Discussion

**09:05-09:20** Mammographic density  
**Jack Cuzick, UK**

**09:20-09:30** Validation of iPrevent, an online breast cancer risk assessment and risk management decision support tool  
**Kelly-Anne Phillips, Australia**

**08:30-09:30** **Parallel Session 3:  
Keeping patients on their endocrine treatments**

Hall B

**Chairpersons:** **Nicole McCarthy, Australia**  
**Lisa Sheeran, Australia**

**08:30-08:50** The biology of endocrine side effects  
**Mitch Dowsett, Australia**

**08:50-09:05** Below the breast: Managing genitourinary symptoms  
**Martha Hickey, Australia**

<b>09:05-09:30</b>	<b>DEBATE:</b> How to best manage endocrine therapy symptoms: Pharma or sweat?
09:05	<b>SWEAT: Prue Cormie, Australia</b>
09:15	<b>PHARMA: Fran Boyle, Australia</b>
09:25	Discussion



**08:30-09:30**      **Parallel Session 4:**  
**Free Papers: Medical oncology**

Hall C

**Chairpersons:**    **Nick Murray, Australia**  
**Catherine Oakman, Australia**

**08:30-08:40**      Neoadjuvant chemotherapy rates for breast cancer in Australia: Are we there yet?  
**Paul Patiniott, Australia**

**08:40-08:50**      Curative Intent Stereotactic Ablative Body Radiotherapy (SABR) in oligometastatic breast cancer: Final results of a Phase I clinical trial  
**Steven David, Australia**

**08:50-09:00**      Cryoablation of breast cancer in metastatic patients. Preliminary experience  
**Claudio Pusceddu, Italy**

**09:00-09:10**      Ribociclib with endocrine therapy for premenopausal women with hormone receptor positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Additional results from the Monaleesa-7 trial  
**Louis Chow, Hong Kong**

**09:10-09:20**      Canassist-breast: Unique immunohistochemistry based test for risk of recurrence prediction for early stage breast cancer patients: A cost-effective, accurate and broad based solution for Asia  
**Manjiri Bakre, India**

**09:20-09:30**      Phase 2 keynote-086 trial: Relationship between response to pembrolizumab and tumor infiltrating lymphocyte (TIL) levels in metastatic triple-negative breast cancer (mTNBC)  
**Sherene Loi, Australia**

**09:30-11:00**      **Plenary Session 5:**  
**Genetics**

Hall A

**Chairpersons:**    **Geoff Lindeman, Australia**  
**Lara Lipton, Australia**

**09:30-10:00**      **DEBATE:** That most patients with breast cancer should be panel tested for germline mutations

09:30      **Yes: Paul James, Australia**

09:40      **No: Marion Harris, Australia**

09:50      Discussion

**10:00-10:30**      The medical implications of panel testing: Platinums/PARPi's  
**Rebecca Dent, Singapore**

**10:30-11:00**      **DEBATE:** That gene carriers diagnosed with cancer should be strongly advised to undergo bilateral mastectomy

10:30      **Yes: James French, Australia**

10:40      **No: Christopher Pyke, Australia**

10:50      Discussion

**11:00-11:30**      *Coffee break and poster viewing*

**11:30-12:30**    **Parallel Session 6:  
Imaging**    **Hall A**

**Chairpersons:**    **Seigo Nakamura, Japan**  
**Belinda Yeo, Australia**

**11:30-11:50**    Assessment of response to neoadjuvant chemotherapy  
**Clair Shadbolt, Australia**

**11:50-12:10**    New paradigms in breast imaging: The 7-8 minutes that make a difference  
**Allison Rose, Australia**

**12:10-12:30**    PET in breast cancer  
**Kate Moodie, Australia**

**11:30-12:30**    **Industry Symposium:  
Clinical controversies in HER2+ early breast cancer**  
*Supported by Roche*

**Hall B**

For full details, please refer to page??

**11:30-12:30**    **Parallel Session 7:  
Free Papers: Surgery/Radiotherapy**    **Hall C**

**Chairpersons:**    **Michael Chao, Australia**  
**Sanjay Warriar, Australia**

**11:30-11:40**    Radioactive iodine seed localization in axilla with sentinel node biopsy (RISAS):  
A Dutch prospective multicenter trial on axillary staging after neoadjuvant  
chemotherapy in node positive breast cancer  
**Natacha Ruysers, Belgium**

**11:40-11:50**    Spy fluorescence angiography: An adjunct to identifying cases suitable for staged  
breast reconstruction  
**Nita Bartlett, Australia**

**11:50-12:00**    Intraoperative Assessment (IOA) of the Sentinel Node (SN) in breast cancer by One Step  
Nucleic acid Assay (OSNA): Warwick experience of over 1100 patients  
**Dayalan Clarke, UK**

**12:00-12:10**    Implications of the St George randomized breast boost trial for reduced volume or  
dose breast radiotherapy strategies  
**Peter Graham, Australia**

**12:10-12:20**    Active monitoring is an acceptable choice for women with low risk ductal carcinoma  
in situ (DCIS): An assessment of quality of life  
**Hannah Bromley, Australia**

**12:20-12:30**    The UK-ANZ NeST (neoadjuvant systemic therapy in breast cancer) multicenter  
collaborative study  
**Stuart McIntosh, UK**

**12:30-13:30**    *Lunch break and poster viewing*



**13:30-14:30**     **Parallel Session 8:  
Controversies in reconstruction**

Hall A

**Chairpersons:**    **Elisabeth Elder, Australia**  
**Andrew Spillane, Australia**

**13:30-14:00**    **DEBATE:** That neoadjuvant RT prior to TM/reconstruction is a better approach than post-mastectomy RT  
13:30    **Yes: Caroline Baker, Australia**  
13:40    **No: Boon Chua, Australia**  
13.50    Discussion

**14:00-14:30**    **DEBATE:** That two-stage implant based reconstruction is rarely indicated in the setting of skin or nipple sparing mastectomy  
14:00    **Yes: James French, Australia**  
14:10    **No: Dean Trotter, Australia**  
14.20    Discussion

**13:30-14:30**     **Industry Symposium:  
New paradigms in the treatment of HR+HER2- mBC: CDK4/6 inhibitors and beyond**  
*Supported by Novartis*

Hall B

For full details, please refer to page??

**14:30-15:50**     **Plenary Session 9:  
Adjuvant endocrine therapy**

Hall A

**Chairpersons:**    **Stephen Johnston, UK**  
**Linda Vahdat, USA**

**14:30-14:40**    What is the ER/PR threshold at which endocrine therapy should be prescribed, or may be relied upon?  
**Nirmala Pathmanathan, Australia**

**14:40-15:10**    **DEBATE:** That topical oestrogens are an acceptable treatment in pts with HR+ve early breast cancer  
14:40    **Yes: Yoland Antill, Australia**  
14:50    **No: Catherine Oakman, Australia**  
15:00    Discussion

**15:10-15:20**    Update on SOFT/TEXT  
**Prue Francis, Australia**

**15:20-15:50**    **DEBATE:** That 10 years of AET is overtreatment  
15:20    **Yes: Janice Tsang, Hong Kong**  
15:30    **No: Nicole McCarthy, Australia**  
15:40    Discussion

15:50-16:10     *Coffee break and poster viewing*

**16:10-17:30**    **Parallel Session 10:  
Molecular assays**

Hall A

**Chairpersons:**    **Bruce Mann**, *Australia*  
**Louis Chow**, *Hong Kong*

**16:10-16:25**    The case for using Oncotype DX  
**Virginia Kaklamani**, *USA*

**16:25-16:40**    The case for using Endopredict  
**Mitch Dowsett**, *UK*

**16:40-16:55**    The case for using Mammaprint  
**Alastair Thompson**, *USA*

**16:55-17:10**    The case for using Prosigna  
**Janice Tsang**, *Hong Kong*

**17:10-17:25**    The case for rarely using an assay  
**Belinda Yeo**, *Australia*

**17:25-17:30**    Discussion

**16:10-17:30**    **Parallel Session 11:  
Life after breast cancer**

Hall B

**Chairperson:**    **Lesley Stafford**, *Australia*

**16:10-16:40**    Risking another cancer: Who should have a mastectomy/CPM?  
**Laura Esserman**, *USA*

**16:40-17:00**    Motivational interviewing: How to get the best lifestyle outcomes from your patients  
**Sarah Hardcastle**, *Australia*

**17:00-17:30**    Brains (cognitive decline) and breast cancer  
**Adam Walker**, *Australia*



## Saturday, October 13, 2018

**07:00-08:30** **Morning Industry Symposium:**  
**Old favourites, new strategies: Chemotherapy and the treatment of MBC**  
*Supported by Eisai*

Hall B

*Breakfast will be served prior to the session*

For full details, please refer to page??

**07:00-08:30** **Morning Industry Symposium:**  
**Attractive techniques for localisation and staging: Tools for everyone**  
*Supported by EBOS and Magseed*

Hall C

*Breakfast will be served prior to the session*

For full details, please refer to page??

**08:30-09:30** **Parallel Session 12:**  
**DCIS**

Hall A

**Chairpersons:** **Christopher Pyke**, *Australia*  
**Yvonne Zissiadis**, *Australia*

<b>08:30-09:00</b>	<b>DEBATE:</b> That RT after WE for DCIS is usually overtreatment
08:30	<b>Yes: Laura Esserman</b> , <i>USA</i>
08:40	<b>No: Lori Pierce</b> , <i>USA</i>
08:50	Discussion

**09:00-09:20** Active surveillance is an option for low-risk DCIS  
**Christobel Saunders**, *Australia*

**09:20-09:30** Discussion

**08:30-09:30** **Parallel Session 13:**  
**Topics in chemotherapy**

Hall B

**Chairpersons:** **Rebecca Dent**, *Singapore*  
**Elgene Lim**, *Australia*

<b>08:30-09:00</b>	<b>DEBATE:</b> That dose-dense chemotherapy should be the standard for all subtypes of early breast cancer
08:30	<b>Yes: Linda Vahdat</b> , <i>USA</i>
08:40	<b>No: Richard de Boer</b> , <i>Australia</i>
08:50	Discussion

**09:00-09:15** New strategies in early stage TNBC  
**Stacy Moulder**, *USA*

**09:15-09:30** Will NGS become a standard part of management of breast cancer?  
**Sarah-Jane Dawson**, *Australia*

**08:30-09:30**     **Parallel Session 14:**  
**Free Papers: Screening/Treatment effects/Supportive care**

Hall C

**Chairpersons:**    **Jocelyn Lippey, Australia**  
                          **Kerry Shanahan, Australia**

**08:30-08:40**     Liposuction for advanced breast cancer-related lymphoedema: Outcomes of a multidisciplinary team approach

**John Boyages, Australia**

**08:40-08:50**     Identification of breast cancer survivors' side effects and supportive care needs

**Christina Kozul, Australia**

**08:50-09:00**     Physical function following breast reconstructive surgery: Are musculoskeletal side-effects a problem?

**Deirdre McGhee, Australia**

**09:00-09:10**     Patient reported experiences from the persephone early breast cancer trial

**Janet Dunn, UK**

**09:10-09:20**     Prospective three-arm triple-blinded comparative study for breast cancer screening in low resource setting countries with a noninvasive and low-cost technique using a handheld point-of-care medical device (iBreastexam)

**S.P. Somashekhar, India**

**09:20-09:30**     Health system barriers to the provision of breast reconstruction options in Australia: Improving informed choice through appropriate referral

**Kathy Flitcroft, Australia**

**09:30-11:00**     **Plenary Session 15:**  
**Loco-Regional therapy**

Hall A

**Chairpersons:**    **Caroline Baker, Australia**  
                          **Boon Chua, Australia**

**09:30-10:00**     **DEBATE:** That all patients with axillary nodal disease pre-NACT should have axillary dissection or radiation

09:30     **Yes: Yvonne Zissiadis, Australia**

09:40     **No: Jane O'Brien, Australia**

09:50     Discussion

**10:00-10:20**     The implications of the AMAROS study

**Lori Pierce, USA**

**10:20-11:00**     **DEBATE:** That regional nodal radiation is appropriate for most patients with nodal disease

10:20     **Yes: Reshma Jagsi, USA**

10:35     **No: Louis Chow, Hong Kong**

10:50     Discussion

**11:00-11:30**     *Coffee break and poster viewing*



11:30-13:00

**Parallel Session 16:  
Local therapy**

Hall A

**Chairpersons:** **James French**, *Australia*  
**Jane Fox**, *Australia*

11:30-12:00

**DEBATE:** Margins: That “no tumour on ink” is a dangerous over-simplification

11:30

**Yes:** **Ian Campbell**, *New Zealand*

11:40

**No:** **Raghu Ram**, *India*

11:50

Discussion

12:00-12:30

The status of intra-operative techniques for localization/margin assessment  
**Alistair Thompson**, *USA*

12:30-13:00

**DEBATE:** That IORT is ready for prime time

12:30

**Yes:** **Dennis R. Holmes**, *USA*

12:40

**No:** **Michael Chao**, *Australia*

12:50

Discussion

11:30-13:00

**Industry Symposium:  
Key issues around bone health**  
*Supported by Amgen*

Hall B

For full details, please refer to page??

10:30-13:00

**Breast Cancer Network Australia:  
Metastatic breast cancer**

Hall C

13:00-14:00

*Lunch break and poster viewing*

14:00-15:00

**Parallel Session 17:  
Exercise and lymphoedema**

Hall A

**Chairpersons:** **Kerry Shanahan**, *Australia*  
**Lisa Sheeran**, *Australia*

14:00-14:20

Surgery for lymphoedema: A new paradigm  
**Ramin Shayan**, *Australia*

14:20-14:40

Prescribing exercise and putting it into practice  
**Prue Cormie**, *Australia*

14:40-15:00

Wearable technology and influencing health behaviours  
**Sarah Hardcastle**, *Australia*



**14:00-15:00**    **Parallel Session 18:  
CNS metastases**

Hall B

**Chairpersons:**    **Minjae Lah, Australia**  
**Stacy Moulder, USA**

**14:00-14:20**    Molecular pathology of CNS metastases  
**Sunil R. Lakhani, Australia**  
**Stacy Moulder, USA**

**14:20-14:40**    Local therapy for CNS metastases: The roles of surgery, SRS and WBRT in 2018  
**Claire Phillips, Australia**

**14:40-15:00**    Drug treatment for CNS metastasis  
**Arlene Chan, Australia**

**14:00-15:00**    **Parallel Session 19:  
Breast surgery**

Hall C

**Chairpersons:**    **Ian Campbell, New Zealand**  
**Raghu Ram, India**

**14:00-14:15**    Onco-anaesthesia: Is anaesthetic technique a risk factor for outcome?  
**Bernhard Riedel, Australia**

**14:15-14:45**    **DEBATE:** That percutaneous ablation is a useful treatment option in early breast cancer  
14:15    **Yes: Dennis Holmes, USA**  
14:25    **No: Andrew Spillane, Australia**  
14:35    Discussion

**14:45-15:00**    How should quality of life be assessed after breast cancer surgery  
**Elisabeth Elder, Australia**

**15:00-16:15**    **Plenary Session 20:  
Breast Cancer 2025**

Hall A

**Chairpersons:**    **Christobel Saunders, Australia**  
**Yvonne Zissiadis, Australia**

**15:00-15:15**    Breast cancer prevention in 2025  
**Jack Cuzick, UK**

**15:15-15:30**    A pathologist's view of breast cancer in 2025  
**Sunil R. Lakhani, Australia**

**15:30-15:45**    How might immunotherapy be used in breast cancer?  
**Sherene Loi, Australia**

**15:45-16:00**    A radiation oncologist's view of breast cancer in 2025  
**Reshma Jagsi, USA**

**16:00-16:15**    A surgeon's view of breast cancer in 2025  
**Laura Esserman, USA**

**16:15-16:30**    **Congress closing and Award presentation**

Hall A

**Chairpersons:**    **Christobel Saunders, Australia**  
**Yvonne Zissiadis, Australia**  
**Bruce Mann, Australia**



# POSTER PRESENTATIONS

## Friday, October 12, 2018

### Adjuvant endocrine therapy

- P01 ANTI-HORMONAL THERAPY ALONE IN N1 STAGE BREAST CANCER PATIENTS WITH HORMONE RECEPTOR POSITIVE AND HER-2 NEGATIVE  
**Sung-ui Jung**, *South Korea*
- P02 MALE BREAST CANCER IN AUSTRALIA: COMPLIANCE WITH TREATMENT KEY PERFORMANCE INDICATORS – 99,768 BREAST CANCERS OVER A 10 YEAR PERIOD  
**Chris Lomma**, *Australia*
- P03 SYSTEMIC ADJUVANT TREATMENT RECOMMENDATIONS AND COMPLIANCE IN AUSTRALIAN PATIENTS WITH EARLY BREAST CANCER  
**Chris Lomma**, *Australia*

### Bone health

- P04 PERCUTANEOUS PEDICLE SCREW FIXATION FOLLOWED BY CEMENTOPLASTY: A MINIMALLY INVASIVE TECHNIQUE FOR SPINAL METASTASIS IN BREAST CANCER PATIENTS  
**Claudio Pusceddu**, *Italy*

### Breast cancer genetics

- P05 PREVALENCE OF OESTROGEN RECEPTOR POSITIVE BREAST CANCER IN OBESITY PATIENTS: A RETROSPECTIVE STUDY  
**Nur Aziah Binti Adib Anuar**, *Malaysia*
- P06 LVI IS IT MORE WORSE PREDICT OUTCOME THAN WE BELIEVE WE KNOW ABOUT IT? SYSTEMIC REVIEW OF SINGLE INSTITUTE IN SAUDI ARABIA  
**Abdulaziz Alhamad**, *Saudi Arabia*
- P07 METHYLATION STATUS OF MGMT AND MEG3 GENE'S PROMOTERS IN TRIPLE-NEGATIVE BREAST CANCER  
**Sylwia Sloniec**, *Poland*

### Breast imaging

- P08 FEATURE OF THE BREAST LESION CAN BE DECEPTIVE: MIMICKERS OF BREAST MALIGNANCY  
**Visnja Baksa Reynolds**, *Singapore*
- P09 SHEAR WAVE ULTRASOUND AND HIGH MAMMOGRAPHIC BREAST DENSITY (HMBD); A PILOT STUDY OF BREAST STIFFNESS REDUCTION IN PRE-MENOPAUSAL WOMEN WITH HMBD  
**Stephen Birrell**, *Australia*
- P10 LITERATURE REVIEW AND CASE REPORT OF GRANULAR CELL TUMOUR IN BREAST  
**Amy Cao**, *Australia*
- P11 THE IMPACT OF PRE-OPERATIVE MRI IN THE MANAGEMENT OF INVASIVE LOBULAR CARCINOMA OF THE BREAST  
**Jennifer Chang**, *New Zealand*
- P12 KEEP CALM, IT'S JUST `MOOBS`  
**Mei Chan Chin**, *Australia*
- P13 THE BRILLIANCE OF CONTRAST ENHANCED SPECTRAL MAMMOGRAPHY (CESM)  
**Laurence Gluch**, *Australia*
- P14 COMPARISON OF USEFULNESS OF ULTRASOUND AND MRI FOR DIAGNOSIS OF SILICON BREAST IMPLANT RUPTURE  
**Naoya Gomi**, *Japan*

- P15 FEATURES OF IMAGE FINDINGS OF DIGITAL BREAST TOMOSYNTHESIS (DBT) UNDETECTED BREAST CANCER  
**Mari Kikuchi, Japan**
- P16 APPROACHING BREAST IMPLANT ASSOCIATED COMPLICATION WITH ULTRASOUND AND CHECKLIST  
**Angela Soeun Lee, South Korea**
- P17 SQUAMOUS CELL METAPLASIA OF LACTIFEROUS DUCTS IN MALE PATIENTS  
**Rachael Manning, Australia**
- P18 WHICH IS THE BETTER METHOD TO DETECT ABNORMALITIES BY VISUAL ESTIMATE OR VOLPARA™ FOR WOMEN WITH DENSE BREAST?  
**Misaki Matsuyanagi, Japan**
- P19 FALSE NEGATIVE ON COMPUTER-AIDED DETECTION APPLICATION IN PREOPERATIVE AUTOMATED BREAST ULTRASOUND OF BREAST CANCER PATIENTS  
**Jiwon Rim, South Korea**
- P20 IMPACT OF PRE-OPERATIVE BREAST MRI ON BREAST CANCER TREATMENT PLANNING  
**Masuma Sarker, UK**
- P21 THE BREAST CANCER RELATED-RISKS IN WOMEN WITH DENSE BREAST TISSUE IS CLARIFIED BY USING VOLPARA™  
**Terumasa Sawada, Japan**
- P22 DIAGNOSTIC VALIDITY OF SURGEON-PERFORMED BREAST ULTRASOUND FOR FEMALES WITH PALPABLE BREAST MASSES  
**Apple Valparaiso, Philippines**
- P23 THE DIFFERENTIAL DIAGNOSIS OF THE BREAST FINDINGS USING AUTOMATED BREAST VOLUME SCANNER (ABVS) AND ADVANCED ELASTOGRAPHY  
**Mihaela Vancu, Romania**
- P24 INFLUENCE OF PRE-OPERATIVE BREAST CANCER LOCALIZATION TECHNIQUES ON RATES OF SENTINEL LYMPH NODE VISUALIZATION WITH PREOPERATIVE LYMPHOSCINTIGRAPHY  
**Shipra Verma, Australia**

### Breast reconstruction

- P25 PREPECTORAL IMMEDIATE IMPLANT-BASED RECONSTRUCTION USING BRAXON: AN ACELLULAR DERMAL MATRIX – NATIONAL AUDIT FROM THE UNITED KINGDOM  
**Dayalan Clarke, UK**

### Endocrine resistance

- P26 RIBOCICLIB + FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR+), HER2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): RESULTS FROM MONALEESA-3  
**Arlene Chan, Australia**
- P27 SINGLE CENTER STUDY IN THE PHILIPPINES ON ERIBULIN MESYLATE IN METASTATIC BREAST CANCER FROM 2013 - 2016  
**Amabelle Trina Gerona, Philippines**

### Molecular assays

- P28 OPTIMA: A PROSPECTIVE RANDOMISED TRIAL TO VALIDATE THE CLINICAL UTILITY AND COST-EFFECTIVENESS OF GENE EXPRESSION TEST-GUIDED CHEMOTHERAPY DECISIONS IN HIGH CLINICAL RISK EARLY BREAST CANCER  
**Janet Dunn, UK**
- P29 TUMOR MICROENVIRONMENT AND ITS PHARMACOLOGICAL MODULATION IN A BREAST CANCER MODEL: PARALLELS TO SKIN WOUND HEALING  
**Peter Gal, Slovakia**
- P30 EXPLORING IN VITRO ANDROGEN BIOASSAYS AS A CLINICAL TOOL FOR BREAST CANCER  
**Rachel Lund, New Zealand**



## Neoadjuvant therapy

- P31 PATHOLOGIC OUTCOMES OF HER2 POSITIVE NON METASTATIC BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT DUAL ANTI HER2 THERAPY AND TAXANE AT SYDNEY ADVENTIST HOSPITAL (SAH)  
**Joseph Do Woong Choi, Australia**
- P32 DESIGN OF PERSIA: PERTUZUMAB STUDY FOR HER2-POSITIVE NON-METASTATIC BREAST CANCER IN THE NEOADJUVANT SETTING IN AUSTRALIA  
**Richard De Boer, Australia**
- P33 PREDICTIVE FACTORS OF STABLE OR PROGRESSIVE DISEASE DURING ANTHRACYCLINE WITH/WITHOUT TAXANE-BASED NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER  
**Ji Young Kim, South Korea**

## Prevention

- P34 EARLY-LIFE BODY FATNESS IN RELATION TO TEXTURE VARIATION ON A MAMMOGRAM  
**Hannah Oh, South Korea**
- P35 COMPLIANCE WITH MULTIDISCIPLINARY TEAM MEETING TREATMENT RECOMMENDATIONS  
**Amali Samarasinghe, Australia**

## Radiotherapy

- P36 DOES THE TUMOR BED SURGICAL CLIPS AFFECT DOSIMETRIC CHANGES IN THREE-DIMENSIONAL FIELD-IN-FIELD WHOLE-BREAST IRRADIATION TECHNIQUES FOR PATIENTS UNDERGOING BREAST CONSERVING SURGERY?  
**Dong Soo Lee, South Korea**

## Supportive care

- P37 IMAGING-PROVEN VENOUS THROMBOEMBOLISM AMONG BREAST CANCER PATIENTS IN A TERTIARY HOSPITAL IN THE PHILIPPINES FROM 2010-2015  
**Amabelle Trina Gerona, Philippines**
- P38 THE EFFICACY OF BILASTINE FOR TAXANE REGIMENS INDUCED RASH  
**Taizo Hirata, Japan**
- P39 FEASIBILITY OF SEGMENTAL ECW/TBW RATIO FOR MILD TO MODERATE DEGREE BREAST CANCER-RELATED LYMPHEDEMA: CORRELATION WITH TAPE CIRCUMFERENTIAL VOLUME MEASUREMENT  
**Woo Gyeong Kim, South Korea**
- P40 CONSENT IN THE AGE OF WHITAKER AND MONTGOMERY: TIPTOEING THROUGH THE MINEFIELD OF PATIENT AUTONOMY  
**Mona Tan, Singapore**

## Survivorship

- P41 LYMPHATIC MICROSURGICAL PREVENTING HEALING APPROACH (LYMPHA): A SYSTEMATIC REVIEW  
**Natalia Garibotto, Australia**
- P42 PLEOMORPHIC LOBULAR BREAST CANCER: DOES MORPHOLOGY MATTER?  
**Laurence Gluch, Australia**
- P43 ETHNIC DISPARITIES IN THE INCIDENCE OF PHYLLODES TUMOURS AT COUNTIES MANUKAU HEALTH  
**Megan Grinlinton, New Zealand**
- P44 UTILITY OF SERUM TUMOUR MARKER VELOCITY OF CANCER ANTIGEN 15-3 (CA15-3) AND CARCINOEMBRYONIC ANTIGEN (CEA) IN BREAST CANCER SURVEILLANCE  
**Jun Xian Hing, Singapore**
- P45 TREATMENT PATTERNS AND CLINICAL OUTCOMES IN ELDERLY BREAST CANCER PATIENTS  
**Eunyoung Kang, South Korea**

- P46 IMPACT OF VITAMIN D ON BREAST CANCER OUTCOME  
**Trisha Khoo, Australia**
- P47 OLIGOMETASTATIC BREAST CANCER: CAN WE EVER SAY CURE?  
**Tahlia Molinaro, Australia**
- P48 QUALITY OF LIFE AND BODY IMAGE IN WOMEN WITH SURGERY FOR BREAST CANCER IN SINGAPORE  
**Siau Wei Tang, Singapore**
- P49 ESTABLISHING ROUTINE COLLECTION OF PATIENT-REPORTED OUTCOMES VIA THE BREASTSURGANZ QUALITY AUDIT: A PROOF-OF-PRINCIPLE PROJECT TO TEST FEASIBILITY  
**David Walters, Australia**
- P50 BREAST CANCER FOLLOW-UP: THE PATIENTS PERSPECTIVE  
**Maggie Wilcox, UK**
- P51 PHYSIOTHERAPY MANAGEMENT OF BREAST CANCER TREATMENT-RELATED FATIGUE, LYMPHOEDEMA, METASTATIC AND RADIATION-INDUCED BRACHIAL PLEXOPATHY: A CASE REPORT  
**Wai Yeung, Australia**
- P52 WALKING THE BOUNDARIES: IS THE 6-MINUTE WALK TEST ACHIEVABLE IN AN OUTPATIENT BREAST CLINIC?  
**Lei Ying, Australia**

### Triple negative breast cancer

- P53 HEALTH CARE RESOURCE UTILIZATION FOR PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (mTNBC) IN THE REAL WORLD CLINICAL SETTING: AN OBSERVATIONAL BREAST CANCER (OBTAIN) STUDY FROM AUSTRALIA  
**Elani Bowers, Australia**
- P54 THE MANAGEMENT OF BRCA PATIENTS IN THE WELLINGTON REGION: A 10 YEAR OVERVIEW  
**Sue Hui Ong, New Zealand**
- P55 RADIOGENOMIC ANALYSIS OF TRIPLE NEGATIVE BREAST CANCER: FEATURES OF RADIOMICS AND TRANSCRIPTOMICS  
**Sung Ui Shin, South Korea**

## Saturday, October 13, 2018

### Breast cancer screening

- P01 LOBULAR NEOPLASIA IN BREAST SCREEN SETTING MULTICENTRE STUDY (ST VINCENT AND MONASH) RETROSPECTIVE, DESCRIPTIVE STUDY: 23 YEARS (1993-2016)  
**Parisa Aminzadeh, Australia**
- P02 ZnR/GPR39 MODULATES KCC ACTIVITY IN ESTROGEN NEGATIVE BREAST CANCER CELLS  
**Moumita Chakraborty, Israel**
- P03 ROS-MEDIATED APOPTOSIS INDUCED BY FRUIT POLYPHENOLS IS FOLLOWED BY P38MAPK, ERK1/2 AND THE AKT SIGNALING PATHWAYS MODULATION IN BREAST CARCINOMA MODEL  
**Matus Coma, Slovakia**
- P04 IS ASYMPTOMATIC SURVEILLANCE AFTER STANDARD TREATMENT BENEFICIAL?: A 10 YR-SURVIVAL ANALYSIS OF RECURRENT BREAST CANCER PATIENTS BY DETECTION METHOD OF RECURRENCE  
**Han Shin Lee, South Korea**
- P05 OPTIMISING THE EARLY DETECTION OF BREAST CANCER IN AUSTRALIA  
**Carolyn Nickson, Australia**
- P06 USING THE GAIL MODEL TO RISK-STRATIFY WOMEN FOR BREAST CANCER SCREENING: MODEL VALIDATION ON 40,000 AUSTRALIAN WOMEN ATTENDING BREASTSCREEN  
**Carolyn Nickson, Australia**



- P07 SOME OPTIONS FOR COMBINING QUESTIONNAIRE AND MAMMOGRAPHIC DENSITY MEASURES TO ESTIMATE RISK OF FUTURE INVASIVE BREAST CANCER AND INTERVAL CANCERS IN SCREENED WOMEN  
**Carolyn Nickson, Australia**
- P08 MACHINE LEARNING MODELS FOR POPULATION-LEVEL RISK STRATIFICATION  
**Pietro Procopio, Australia**
- P09 RELIABILITY OF SUSPICION OF MALIGNANT BREAST MASS IN AUTOMATED BREAST ULTRASOUND (ABUS) EXAMINATION: AUTOMATED VERSUS HANDHELD BREAST ULTRASOUND  
**Jiwon Rim, South Korea**

### Breast reconstruction

- P10 SCARLESS LATISSIMUS DORSI FLAP: AN EXCELLENT OPTION FOR LOWER POLE COVER IN IMPLANT BASED RECONSTRUCTION FOR A CHALLENGING SUBSET OF PATIENTS  
**Vanitha Budhavaram, Australia**
- P11 SINGLE PORT LAPAROSCOPIC HARVESTED OMENTAL FLAP FOR IMMEDIATE BREAST RECONSTRUCTION: EXPERIENCE IN SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL  
**Sumin Chae, South Korea**
- P12 DOES IMMEDIATE BREAST RECONSTRUCTION LEAD TO A DELAY IN ADJUVANT CHEMOTHERAPY FOR BREAST CANCER?: A META-ANALYSIS AND SYSTEMATIC REVIEW  
**Patrick Cook, Australia**
- P13 BREAST RECONSTRUCTION IN THE REGIONAL SETTING: 5 YEARS OF EXPERIENCE  
**Daniel Keating, Australia**
- P14 CLINICAL AUDIT REDUCTION MAMMOPLASTY FROM 2011 TO 2016: AN ASSESSMENT OF SURGICAL OUTCOME AND WAITING PERIOD IN A TERTIARY PUBLIC HOSPITAL  
**Jeffrey Smith, Australia**

### DCIS

- P15 ACTIVE MONITORING VERSUS IMMEDIATE TREATMENT FOR WOMEN WITH LOCALISED, LOW-RISK DUCTAL CARCINOMA IN SITU: DOES IT MAKE ECONOMIC SENSE?  
**Hannah Bromley, Australia**
- P16 TRIPLE NEGATIVE DCIS  
**Sayuka Nakayama, Japan**

### Local therapy

- P17 RADIO-GUIDED OCCULT LESION LOCALISATION USING IODINE-125 SEEDS (ROLLIS) IS A SAFE ALTERNATIVE TO HOOK-WIRE LOCALISATION (HWL)  
**Brenno Becker, Australia**
- P18 THE USE OF WIRELESS TECHNOLOGY IN BREAST CANCER: HOW TO START YOUR OWN RADIOGUIDED OCCULT LESION LOCALISATION PROGRAMME USING IODINE – 125 SEEDS (ROLLIS)  
**Brenno Becker, Australia**
- P19 CLINICOPATHOLOGIC PROFILE AND OUTCOMES OF PHYLLODES TUMOR OF THE BREAST: A 10-YEAR REVIEW OF A PHILIPPINE TERTIARY HOSPITAL EXPERIENCE  
**Shiela Macalindong, Philippines**
- P20 CAN METHYLENE BLUE DYE BE USED AS AN ALTERNATIVE TO PATENT BLUE DYE TO FIND THE SENTINEL LYMPH NODE IN BREAST CANCER SURGERY?  
**Omid Rouhbakhshfar, Iran**
- P21 MUCINOUS BREAST CARCINOMA. A SINGLE INSTITUTION EXPERIENCE  
**Nikolaos Salemis, Greece**
- P22 OPTIMAL TREATMENT MODALITY OF PSEUDOANGIOMATOUS STROMAL HYPERPLASIA OF THE BREAST  
**Kwanghyun Yoon, South Korea**

## Locoregional therapy

- P23 LITERATURE REVIEW AND THREE CASE REPORTS OF BREAST FIBROMATOSIS: A MASQUERADE OF BREAST CANCER  
**Amy Cao, Australia**
- P24 A NOVEL PREDICTIVE TOOL FOR HEAVY AXILLARY NODAL INVOLVEMENT IN SENTINEL NODE POSITIVE BREAST CANCER  
**Nipu Jayatilleke, Australia**
- P25 MAGNETIC TRACER USE FOR SENTINEL NODE BIOPSY: INTRODUCTION TO AN AUSTRALASIAN PILOT STUDY  
**Ahrin Anna Morrow, New Zealand**
- P26 IMPACT OF THE AMERICAN COLLEGE OF SURGEONS ONCOLOGY GROUP Z0011 TRIAL ON THE MANAGEMENT OF POSITIVE AXILLARY NODES IN THE AUSTRALIAN SETTING  
**Nicholas K. Ngui, Australia**
- P27 OUTCOMES OF RIB RESECTION FOR BREAST TUMORS EXTENDING TO THE CHEST WALL  
**Kristine Paguirigan, Philippines**
- P28 DISCUSSION ON INDICATIONS OF INTERNAL MAMMARY SENTINEL LYMPH NODE BIOPSY IN BREAST CANCER IN THE ERA OF PRECISION MEDICINE  
**Peng-Fei Qiu, China**
- P29 A PROSPECTIVE COMPARATIVE DOUBLE ARM STUDY OF SLNB WITH ICG BASED TECHNIQUE VERSUS COMBINATION DUAL DYE TECHNIQUE FOR EARLY BREAST CANCER: FIRST INDIAN STUDY  
**S.P. Somashekhar, India**
- P30 THE 'TWINKLE' ARTEFACT: A NOVEL METHOD OF CLIP IDENTIFICATION TO FACILITATE TARGETED AXILLARY SURGERY FOLLOWING NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS  
**Mona Tan, Singapore**
- P31 INDOCYANINE GREEN FLUORESCENCE VERSUS BLUE DYE OR RADIOISOTOPE FOR DETECTION RATE OF SENTINEL LYMPH NODE BIOPSY AND NODES REMOVED IN BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS  
**Sarun Thongvitokomarn, Thailand**
- P32 BREAST CANCER ANATOMIC STAGING WITH RISK SCORE IS SIMPLE TO USE AND EFFECTIVE  
**Ru Xin Wong, Singapore**

## Oncoplastic surgery

- P33 PERFORATOR FLAPS FOR BREAST CONSERVING SURGERY: RESULTS FROM AN EARLY SERIES  
**Nita Bartlett, Australia**
- P34 IMAGING RESULTS FOLLOWING PARTIAL BREAST RECONSTRUCTION WITH CHEST WALL PERFORATOR FLAPS: A QUALITATIVE ANALYSIS WHEN COMPARED TO STANDARD BREAST CONSERVING SURGERY  
**Jesse Hu, Singapore**
- P35 PREOPERATIVE 3D PRINTING TO AID PLANNING IN COMPLEX BREAST PROCEDURES  
**Railya Mousina, Australia**
- P36 DOES ONCOPLASTIC SURGERY HAVE A ROLE IN OPTIMISING BREAST CONSERVATION TREATMENT IN AN ASIAN CONTEXT?  
**Mona Tan, Singapore**
- P37 EFFICACY AND SAFETY OF TRANEXAMIC ACID IN ONCOPLASTIC BREAST SURGERY: A SYSTEMATIC LITERATURE REVIEW  
**Kartik Vasan, Australia**
- P38 PRACTICE PATTERNS OF ANTIBIOTIC PROPHYLAXIS IN ONCOPLASTIC BREAST SURGERY: A NATIONWIDE AUSTRALIAN SURVEY  
**Kartik Vasan, Australia**



## Radiotherapy

- P39 ACCELERATED PARTIAL BREAST IRRADIATION (APBI) WITH EXTRACRANIAL STEREOTACTIC RADIOTHERAPY (SBRT) AND EXACTRAC ADAPTIVE GATING IN LOW-RISK EARLY BREAST CANCER: 5-YEAR FOLLOW-UP  
**Angel Acosta Rojas, Spain**
- P40 POST-MASTECTOMY HYPOFRACTIONATED LOCOREGIONAL IRRADIATION (HLRI)  
**Angel Acosta Rojas, Spain**
- P41 HYPOFRACTIONATED RADIOTHERAPY IN LOCALLY ADVANCED BREAST CANCER AFTER CONSERVATIVE SURGERY  
**Angel Acosta Rojas, Spain**
- P42 HYPOFRACTIONATED ACCELERATED RADIOTHERAPY FOR DUCTAL CARCINOMA IN SITU (DCIS)  
**Angel Acosta Rojas, Spain**
- P43 INTRAOPERATIVE RADIOTHERAPY FOR EARLY STAGE BREAST CANCER AT THE MONASH CANCER CENTRE: FEASIBILITY AND ACUTE TOXICITY  
**Steven David, Australia**
- P44 DEVELOPMENT OF A TREATMENT TECHNIQUE FOR THE AEROFORM™ TISSUE EXPANDER BREAST IMPLANT SYSTEM: A SINGLE DEPARTMENT EXPERIENCE  
**Jennie Gilliman, Australia**
- P45 EVALUATION OF SETUP ACCURACY FOR PRONE BREAST RADIOTHERAPY WITH A 3D SURFACE IMAGING SYSTEM  
**Sunmi Jo, South Korea**
- P46 DEEP INSPIRATION BREATH HOLD COMPLIANCE RATE AT SIMULATION AT GENESISCARE VICTORIA  
**Cynleen Kai, Australia**
- P47 COMPARING EVIDENCE-BASED RECOMMENDATIONS FOR RADIOTHERAPY USE AGAINST ROUTINE PRACTICE IN BREAST CANCER  
**Roya Merie, Australia**
- P48 UTILITY OF DEEP INSPIRATORY BREATH HOLD (DIBH) IN THE RADIOTHERAPEUTIC MANAGEMENT OF RIGHT SIDED BREAST CANCER  
**Andrew See, Australia**
- P49 PARADIGMS IN BREAST CANCER MANAGEMENT IN PREVIOUSLY AUGMENTED BREASTS: TIME FOR A CHANGE?  
**Kartik Vasani, Australia**



## Molecular Assays

- P50 NETRIN-1 EXPRESSION IN BREAST CANCER  
**Shyr-Ming Sheen-Chen, Taiwan**



# INDUSTRY

## Melbourne International Joint Breast Congress





## LIST OF SUPPORTERS

The MIBC Congress would like to thank the supporters. It is with the support of the industry that MIBC can continue in its mission to promote research and education and to disseminate new knowledge.

### GOLD



### SILVER



### BRONZE



### SUPPORTERS



# LIST OF EXHIBITORS





# INDUSTRY SYMPOSIA

## Friday, October 12, 2018

**07:00-08:30** **Morning Industry Symposium:**  
**Practice-changing new perspectives on genomic profiling in the management of HR+, HER2- Early Breast Cancer**  
*Supported by Genomic Health*

Hall A

*Breakfast will be served prior to the session*

**Chairpersons:** **Bruce Mann, Australia**  
**Elgene Lim, Australia**

**07:15-07:20** Introduction  
**Elgene Lim, Australia**

**07:20-07:50** Level 1 Evidence on the Oncotype DX Breast Recurrence Score® Assay and Implications for Clinical Practice  
**Virginia Kaklamani, USA**

**07:50-08:25** Panel Discussion/Case Studies

Chairs:  
**Bruce Mann, Australia**  
**Elgene Lim, Australia**

Panelists:  
**Virginia Kaklamani, USA**  
**Richard de Boer, Australia**  
**Cindy Mak, Australia**

**07:00-08:30** **Morning Industry Symposium:**  
**CDK4/6 inhibitors in advanced breast cancer: The future is now**  
*Supported by Pfizer*

Hall B

*Breakfast will be served prior to the session*

**Chairpersons:** **Arlene Chan, Australia**  
**Catherine Oakman, Australia**

**07:15-07:45** The science behind CDK4/6 inhibition  
**Javier Cortes, Spain**

<b>07:45-08:15</b>	<b>DEBATE:</b> That all 1st line stage 4 ER+/HER2-patients should have a CDK4/6 inhibitor
07:45	<b>Yes: Rebecca Dent, Singapore</b>
07:55	<b>No: Nick Murray, Australia</b>
08:05	Discussion

**08:15-08:30** Discussion

**11:30-12:30**    **Industry Symposium:**  
**Clinical controversies in HER2+ early breast cancer**  
*Supported by Roche*

Hall B

**Chairpersons:**    **Fran Boyle, Australia**  
**Catherine Shannon, Australia**

**11:30-11:45**    Neo-adjuvant therapy in HER2 positive disease  
**Javier Cortes, Spain**

**11:45-12:15**    **DEBATE:** That all high-risk adjuvant HER2 patients should receive dual antibody therapy  
11:45    **Yes: Javier Cortes, Spain**  
11:55    **No: Nicholas Wilcken, Australia**  
12:05    Discussion

**12:15-12:30**    Case studies: HER2 +ve neo-adjuvant and adjuvant setting  
**Moderator: Fran Boyle, Australia**

**Javier Cortes, Spain**  
**Richard de Boer, Australia**  
**Nicholas Wilcken, Australia**

**13:30-14:30**    **Industry Symposium:**  
**New paradigms in the treatment of HR+HER2- mBC: CDK4/6 inhibitors and beyond**  
*Supported by Novartis*

Hall B

**Chairpersons:**    **Richard de Boer, Australia**  
**Belinda Yeo, Australia**

**13:30-13:35**    Welcome  
**Richard de Boer, Australia**  
**Belinda Yeo, Australia**

**13:35-13:55**    Role of CDK4/6 Inhibitors in overcoming endocrine resistance: Are they all the same?  
**Stephen Johnston, UK**

**13:55-14:10**    CDK4/6 Inhibitors: The Australian experience, and what to do after progression?  
**Elgene Lim, Australia**

**14:10-14:30**    Case studies and panel discussion



## Saturday, October 13, 2018

**07:00-08:30** **Morning Industry Symposium:**  
**Old favourites, new strategies: Chemotherapy and the treatment of MBC**  
*Supported by Eisai*

Hall B

*Breakfast will be served prior to the session*

**Chairpersons:** **Nicole McCarthy, Australia**  
**Chris Hart, Australia**

**07:15-07:45** How can we partner chemotherapy with immunotherapy?  
**Javier Cortes, Spain**

**07:45-08:15** In the era of CDK inhibition and targeted agents for MBC, does chemotherapy still have a place?  
**Linda Vahdat, USA**

**08:15-08:30** Discussion

**07:00-08:30** **Morning Industry Symposium:**  
**Attractive techniques for localisation and staging: Tools for everyone**  
*Supported by EBOS and Magseed*

Hall C

*Breakfast will be served prior to the session*

**Chairperson:** **Bruce Mann, Australia**

**07:15-07:35** Magtrace for sentinel node localisation  
**Alastair Thompson, USA**

**07:35-08:00** Targeted Axillary Dissection with Magseed  
**Abigail Caudle, USA**

**08:00-08:25** Discussion

**11:30-13:00** **Industry Symposium:**  
**Key issues around bone health**  
*Supported by Amgen*

Hall B

**Chairperson:** **Nicholas Wilcken, Australia**

**11:30-12:00** **DEBATE:** That a bone targeted agent should be routine for post-menopausal HR+ve patients

11:30 **Yes: Arlene Chan, Australia**

11:40 **No: Catherine Shannon, Australia**


11:50 Discussion

**12:00-12:20** Bone agents for stage 4 disease: How long, for how often and at what cost?  
**Richard de Boer, Australia**

**12:20-12:40** The mythology of Vitamin D in disease  
**Ego Seeman, Australia**

**12:40-13:00** Discussion

# FLOOR PLAN




- |   |                       |                                       |
|---|-----------------------|---------------------------------------|
| 1 Bio-Strategy                            | 14 Medilink Australia | 27 ICON Group                         |
| 2 Melbourne Pathology /<br>Sonic Genetics | 15 Surgeons Choice    | 28 J&J                                |
| 3 alpha XRT                               | 16 Spiran             | 29 Medical Specialties<br>Australasia |
| 4 Bard                                    | 17 Aspen Australia    | 30 Roche                              |
| 5 BCNA                                    | 18 Hologic            | 31 Volpara Solutions                  |
| 6 Defries                                 | 19 Aurora BioScience  | 32 Endotherapeutics                   |
| 7 Martix Surgical                         | 20 GEHealthcare       | 33 Integra                            |
| 8 & 9 Zeiss                               | 21 Lilly Barista Cart | 34 Pfizer                             |
| 10 Myriad                                 | 22 Smith and Nephew   | 35 Regional Healthcare                |
| 11 Specialized Therapeutics               | 23 GRC Surgical       | 36 Device Technologies                |
| 12 Eisai                                  | 24 Amgen              | 37 ANSTO                              |
| 13 Surgical Supplies Aus.                 | 25 Novartis           | 38 EBOS/Magseed                       |
|   | 26 LifeHealthcare     |                                       |



# 5th World Congress on **Controversies** in Breast Cancer

hosted by  
**University of California, San Francisco (UCSF)**

Save  
the Date



September 5-7, 2019  
San Francisco, CA, USA

[www.cobrca.org](http://www.cobrca.org)

